WallStreetZenWallStreetZen

NASDAQ: APVO
Aptevo Therapeutics Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their APVO stock forecasts and price targets.

Forecast return on equity

Is APVO forecast to generate an efficient return?

Forecast return on assets

Is APVO forecast to generate an efficient return on assets?

APVO revenue forecast

What is APVO's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$18.9M
Avg 2 year Forecast
$57.9M
Avg 3 year Forecast
$77.1M

APVO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
APVO$0.68N/AN/A
ALLR$1.37N/AN/A
BPTS$9.70N/AN/A
VRAX$0.66N/AN/A
SPRC$1.21N/AN/A

Aptevo Therapeutics Stock Forecast FAQ

What is APVO's revenue growth forecast for 2026-2028?

(NASDAQ: APVO) Aptevo Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.

Aptevo Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast APVO's revenue for 2026 to be $10,061,131, with the lowest APVO revenue forecast at $10,061,131, and the highest APVO revenue forecast at $10,061,131. On average, 1 Wall Street analysts forecast APVO's revenue for 2027 to be $30,908,904, with the lowest APVO revenue forecast at $30,908,904, and the highest APVO revenue forecast at $30,908,904.

In 2028, APVO is forecast to generate $41,151,413 in revenue, with the lowest revenue forecast at $41,151,413 and the highest revenue forecast at $41,151,413.

If you're new to stock investing, here's how to buy Aptevo Therapeutics stock.

What is APVO's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: APVO) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is APVO's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: APVO) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.